Clinical trials: Eye Manifestations
Presbyopia, Near Vision
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
- Conditions
- Presbyopia, Near Vision, Miosis, Eye Diseases
- Trial name
- NCT06045299
- Testing
- Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution
- Where
- 19 sites in China
- Volunteers
- 300 people
- Sponsor
- Corxel Pharmaceuticals
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
Diabetic Macular Edema
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab.
- Trial name
- NCT05959304
- Testing
- brolucizumab
- Where
- 8 sites in India
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLIMMER (NCT04603937)
- Testing
- KSI-301, Aflibercept
- Where
- 72 sites in United States, Czechia and 6 more
- Volunteers
- 459 people
- Sponsor
- Kodiak Sciences Inc
Achromatopsia
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
This is a longer-term follow-up study of patients with achromatopsia associated with defects in CNGA3 who participated in a clinical trial in which they received AAV-CNGA3 retinal gene therapy, or of patients with achromatopsia…
- Trial name
- NCT03278873
- Testing
- Prior exposure to AAV-CNGA3 or AAV-CNGB3
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- MeiraGTx UK II Ltd
Refractive Errors
Direct Comparison of SVOne Obtained Refraction to Subjective Manifest Refraction
The purpose of the study is to compare the final glasses prescription based on refraction obtained with SVOne device to the final prescription obtained via subjective manifest refraction.
- Trial name
- NCT03222661
- Testing
- Refraction
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Smart Vision Labs
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT04658199
- Testing
- UCB0107 (bepranemab)
- Where
- 11 sites in Belgium, Germany and 2 more
- Volunteers
- 19 people
- Sponsor
- UCB Biopharma SRL
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with…
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05176717
- Testing
- QR-421a
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Laboratoires Thea
Achromatopsia
Gene Therapy for Achromatopsia (CNGB3)
A clinical trial of AAV - CNGB3 retinal gene therapy for patients with achromatopsia
- Trial name
- CNGB3 (NCT03001310)
- Testing
- AAV - CNGB3
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- MeiraGTx UK II Ltd
Post Surgical Ocular Inflammation
A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.
- Trial name
- NCT04222725
- Testing
- TRS01 eye drops
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Tarsier Pharma
Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD)
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
This is an observational study in which only data are collected from people who have already been prescribed aflibercept 8 mg by their own doctors.
- Conditions
- Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME)
- Trial name
- NCT06075147
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in Australia, Canada and 16 more
- Volunteers
- 2,500 people
- Sponsor
- Bayer
Sleep-wake Disorder in Blind Individuals
Patient Registry of Blind Subjects With Sleep-related Problems
Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness.
- Trial name
- NCT01195558
- Testing
- Data collection on blindness and sleep problems
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Vanda Pharmaceuticals
Blindness, Acquired
Early Feasibility Study of the Orion Visual Cortical Prosthesis System
This is an early feasibility study of a new device, the Orion Visual Cortical Prosthesis System. The device is intended to stimulate the surface of the visual cortex to induce visual perception in blind individuals.
- Trial name
- NCT03344848
- Testing
- Orion Visual Cortical Prosthesis System
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Second Sight Medical Products
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Amblyopia, Strabismus
Improving Quality Vision Outcomes in Managed Care Setting While Reducing Cost by Use of Accurate, Automated Screening
Amblyopia ("lazy eye") and strabismus (misaligned eyes) are medical eye conditions that combine as the leading causes of preventable vision loss in children.
- Trial name
- NCT02536963
- Testing
- Pediatric Vision Scanning device, Reference examination
- Where
- United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- Rebiscan, Inc.
Diabetes Mellitus, Macular Edema
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement…
- Trial name
- RISE (NCT00473330)
- Testing
- Ranibizumab
- Volunteers
- 377 people
- Sponsor
- Genentech, Inc.
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Eye Diseases
Study for Collection of Aflibercept Data in Routine Practice
The French CODEX study is designed as a national database to describe, in routine medical practice, functional and anatomical responses to intravitreal Aflibercept injection, in a large population of anti-VGEF-naïve patients…
- Trial name
- CODEX (NCT02811692)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 425 people
- Sponsor
- Bayer
Hearing Loss
Evaluation of In-lab Benefit for Speech-in-noise Intelligibility With Device for Adults With Mild to Moderate Hearing Loss
Evaluation of in-lab benefit for speech-in-noise intelligibility with the device for adults with mild to moderate hearing loss.
- Trial name
- NCT07074769
- Testing
- Evaluation of speech-in-noise intelligibility and listening effort
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Luxottica Group S.p.A.